You may also report side effects to Genentech at (888) 835-2555. PiaSky® is a prescription medicine used to treat a disease called paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ...

Roche Holding AG’s Genentech Inc. unit received U.S. FDA approval on June 20 of Piasky (crovalimab) to treat adults and children 13 and older with paroxysmal nocturnal hemoglobinuria and a body weight ...

and PiaSky (Genentech/Roche), offering new mechanisms for treatment. In just over a year, Fabhalta has gained substantial traction, with physician consideration for first-line use doubling year ...

has been selected by Genentech, a member of the Roche Group, to be in the pharmacy network for PIASKY(R) (crovalimab), approved for the treatment of adult and pediatric patients 13 years of age ...

PiaSky is the first monthly subcutaneous (SC ... our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned ...

Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an ...

Treatment with crovalimab met both coprimary endpoints demonstrating noninferiority to eculizumab for transfusion avoidance and hemolysis control. The Food and Drug Administration (FDA) has ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their ...